Sometimes a stock gets such a brutal assessment that there's really no way to sugarcoat it. During CNBC's "Mad Money Lightning Round" on Thursday, Jim Cramer didn't hold back on Recursion Pharmaceuticals (RXRX), calling it "horrendous" and making it clear he doesn't recommend horrendous stocks. Fair enough.

So what earned this harsh verdict? Start with the earnings report from November 5, which was rough by any standard. Recursion posted a quarterly loss of 36 cents per share when analysts were expecting a loss of 31 cents per share. But the real shock came on the revenue side: the company brought in just $5.175 million against analyst estimates of $16.983 million. Missing revenue expectations by more than two-thirds is the kind of thing that gets people's attention.

Adding to the uncertainty, the company announced a leadership transition. Najat Khan, currently serving as chief R&D and commercial officer, will be taking over as CEO and President from co-founder Chris Gibson. Leadership changes during challenging times can signal either a fresh start or additional turbulence, depending on how you look at it.

Price Action: Despite all this, Recursion Pharmaceuticals shares actually jumped 5.6% on Thursday to close at $4.92. Go figure.

The technical picture is about as clear as mud. The stock is trading 12.2% above its 20-day simple moving average, which suggests some short-term momentum, but it's stuck below its 50-day, 100-day, and 200-day SMAs. That's generally not what you want to see if you're looking for sustained strength.

The RSI sits at 54.50, which is basically neutral territory. No overbought or oversold signals here, meaning momentum could swing either direction. The MACD is above its signal line, which typically indicates bullish momentum, but that needs confirmation given where the stock sits relative to its moving averages.

Without clear support or resistance levels defined, traders are flying a bit blind on where the stock might head next. A push toward the October swing high could signal a breakout, while a slide toward November's swing low would suggest more pain ahead.

Here's the kicker: back in April, RXRX experienced a death cross, with the 50-day SMA dropping below the 200-day SMA. That's a classic bearish signal suggesting continued selling pressure unless the stock can climb back above those moving averages.

Over the past year, RXRX has declined 25.87%, reflecting what you might generously call a challenging longer-term trend. When Cramer calls something horrendous, sometimes the chart agrees.